These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 25594616)

  • 21. NuRD blocks reprogramming of mouse somatic cells into pluripotent stem cells.
    Luo M; Ling T; Xie W; Sun H; Zhou Y; Zhu Q; Shen M; Zong L; Lyu G; Zhao Y; Ye T; Gu J; Tao W; Lu Z; Grummt I
    Stem Cells; 2013 Jul; 31(7):1278-86. PubMed ID: 23533168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An improved method for the derivation of high quality iPSCs in the absence of c-Myc.
    Habib O; Habib G; Choi HW; Hong KS; Do JT; Moon SH; Chung HM
    Exp Cell Res; 2013 Dec; 319(20):3190-200. PubMed ID: 24095950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induced pluripotent stem cells (iPSCs): the emergence of a new champion in stem cell technology-driven biomedical applications.
    Das AK; Pal R
    J Tissue Eng Regen Med; 2010 Aug; 4(6):413-21. PubMed ID: 20084623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induced pluripotent stem cell modeling of malignant hematopoiesis.
    Chao MP; Majeti R
    Exp Hematol; 2019 Mar; 71():68-76. PubMed ID: 30659850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nuclear reprogramming and induced pluripotent stem cells: a review for surgeons.
    Qi SD; Smith PD; Choong PF
    ANZ J Surg; 2014 Jun; 84(6):E1-11. PubMed ID: 23035845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induced Pluripotent Stem Cells: Advances in the Quest for Genetic Stability during Reprogramming Process.
    Turinetto V; Orlando L; Giachino C
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28902128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. iPSCs Derived from Malignant Tumor Cells: Potential Application for Cancer Research.
    Cheng H; Liu C; Cai X; Lu Y; Xu Y; Yu X
    Curr Stem Cell Res Ther; 2016; 11(5):444-50. PubMed ID: 26899393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reprogramming of somatic cells: iPS and iN cells.
    Broccoli V
    Prog Brain Res; 2017; 230():53-68. PubMed ID: 28552235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concise Review: Molecular Cytogenetics and Quality Control: Clinical Guardians for Pluripotent Stem Cells.
    Rohani L; Johnson AA; Naghsh P; Rancourt DE; Ulrich H; Holland H
    Stem Cells Transl Med; 2018 Dec; 7(12):867-875. PubMed ID: 30218497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of epigenome-modifying small molecules in induced pluripotent stem cells.
    Lu J; Kong X; Luo C; Li KK
    Med Res Rev; 2013 Jul; 33(4):790-822. PubMed ID: 22581616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nuclear reprogramming and induced pluripotent stem cells: a review for surgeons.
    Qi SD; Smith PD; Choong PF
    ANZ J Surg; 2014 Jun; 84(6):417-23. PubMed ID: 24894037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in the Production and Application of Induced Pluripotent Stem Cells.
    Mortada I; Bilani N
    Curr Stem Cell Res Ther; 2017; 12(8):637-643. PubMed ID: 28969537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inducing somatic cells into pluripotent stem cells is an important platform to study the mechanism of early embryonic development.
    Cui G; Xu Y; Cao S; Shi K
    Mol Reprod Dev; 2022 Feb; 89(2):70-85. PubMed ID: 35075695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nucleosome organizations in induced pluripotent stem cells reprogrammed from somatic cells belonging to three different germ layers.
    Tao Y; Zheng W; Jiang Y; Ding G; Hou X; Tang Y; Li Y; Gao S; Chang G; Zhang X; Liu W; Kou X; Wang H; Jiang C; Gao S
    BMC Biol; 2014 Dec; 12():109. PubMed ID: 25528259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can controlled cellular reprogramming be achieved using microRNAs?
    Sun X; Fu X; Han W; Zhao Y; Liu H
    Ageing Res Rev; 2010 Oct; 9(4):475-83. PubMed ID: 20601195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epigenetic regulation leading to induced pluripotency drives cancer development in vivo.
    Ohnishi K; Semi K; Yamada Y
    Biochem Biophys Res Commun; 2014 Dec; 455(1-2):10-5. PubMed ID: 25019993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The genomic stability of induced pluripotent stem cells.
    Chen Z; Zhao T; Xu Y
    Protein Cell; 2012 Apr; 3(4):271-7. PubMed ID: 22528751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genome damage in induced pluripotent stem cells: assessing the mechanisms and their consequences.
    Hussein SM; Elbaz J; Nagy AA
    Bioessays; 2013 Mar; 35(3):152-62. PubMed ID: 23172728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methods for making induced pluripotent stem cells: reprogramming à la carte.
    González F; Boué S; Izpisúa Belmonte JC
    Nat Rev Genet; 2011 Apr; 12(4):231-42. PubMed ID: 21339765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cell-of-Origin-Specific 3D Genome Structure Acquired during Somatic Cell Reprogramming.
    Krijger PH; Di Stefano B; de Wit E; Limone F; van Oevelen C; de Laat W; Graf T
    Cell Stem Cell; 2016 May; 18(5):597-610. PubMed ID: 26971819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.